- Home
- FSBC vs DSGN Comparison
FSBC vs DSGN Comparison
Compare FSBC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | DSGN |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 819.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FSBC | DSGN |
|---|---|---|
| Price | $41.96 | $11.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $41.90 | $15.25 |
| AVG Volume (30 Days) | 74.7K | ★ 1.1M |
| Earning Date | 04-27-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 28.32 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.25 | N/A |
| Revenue Next Year | $12.30 | N/A |
| P/E Ratio | $48.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.26 | $3.33 |
| 52 Week High | $42.26 | $17.25 |
Technical Indicators
Market Signals| Indicator | FSBC | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 40.09 |
| Support Level | $39.93 | $9.25 |
| Resistance Level | N/A | $13.54 |
| Average True Range (ATR) | 1.00 | 1.32 |
| MACD | 0.03 | -0.52 |
| Stochastic Oscillator | 78.74 | 16.83 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.